It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
These preclinical studies of ferumoxytol-labeled neural stem cells (NSCs) for magnetic resonance imaging (MRI) cell tracking led to U.S. FDA approval for first-in-human use of this labeling method for NSCs transplanted into brain tumor patients. Ferumoxytol labeling of NSCs did not affect cell viability, growth kinetics, or tumor tropism, and enabled MRI visualization of NSC distribution in vivo. These studies support the clinical development of ferumoxytol labeling of cells for post-transplant MRI visualization and tracking.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Department of Neurosciences, City of Hope National Medical Center and Beckman Research Institute, Duarte, California, USA
2 Frank Laboratory, Radiology and Imaging Sciences, Clinical Center and National Institute of Biomedical Imaging and Bioengineering, NIH, Bethesda, Maryland, USA
3 Department of Pathology, City of Hope National Medical Center and Beckman Research Institute, Duarte, California, USA
4 Department of Radiology, University of Southern California, Los Angeles, California, USA; Department of Pathology, University of Southern California, Los Angeles, California, USA; Department of Biomedical Engineering, CHLA/Keck School of Medicine, University of Southern California, Los Angeles, California, USA
5 Department of Cancer Immunotherapy and Tumor Immunology, City of Hope National Medical Center and Beckman Research Institute, Duarte, California, USA
6 Department of Information Sciences, City of Hope National Medical Center and Beckman Research Institute, Duarte, California, USA
7 Brain Tumor Center, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
8 Division of Neurology, Department of Medicine, UBC Hospital, University of British Columbia, Vancouver, British Columbia, Canada
9 Department of Neurosciences, City of Hope National Medical Center and Beckman Research Institute, Duarte, California, USA; Division of Neurosurgery, City of Hope National Medical Center and Beckman Research Institute, Duarte, California, USA